![Sasha A. Blaug](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sasha A. Blaug
Analyste en capital-investissement chez Portola Capital Partners
Provenance du réseau au premier degré de Sasha A. Blaug
Entité | Type d'entité | Industrie | |
---|---|---|---|
Portola Capital Partners
![]() Portola Capital Partners Investment ManagersFinance Portola Capital Partners is a private equity firm founded in 1992. The firm is headquartered in Silicon Valley, California.
1
| Private Company | Investment Managers | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Sasha A. Blaug via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Burrill LLC
![]() Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor | |
SK Holdings, Inc.
![]() SK Holdings, Inc. BroadcastingConsumer Services Part of Match Group, Inc., SK Holdings, Inc. is a company based in New York, NY. | Broadcasting | Corporate Officer/Principal | |
Korea Evaluation Institute of Industrial Technology
![]() Korea Evaluation Institute of Industrial Technology Miscellaneous Commercial ServicesCommercial Services Korea Evaluation Institute of Industrial Technology operates as a research institute to develop technology for domestic industries. The company is based in Daegu, South Korea. The South Korean company is ultimately controlled by the Government of South Korea. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
GENEXINE, INC. | Biotechnology | Chief Executive Officer | |
AffaMed Therapeutics
![]() AffaMed Therapeutics Pharmaceuticals: MajorHealth Technology AffaMed Therapeutics is a Chinese company focused on providing innovative treatments to patients. The company is based in Shanghai, CN. The company's mission and vision are centered around improving patient access to these treatments. The company has a pipeline of products in development to achieve this goal. and has subsidiaries in United States and Hong Kong. The CEO of the company is Dayao Zhao. | Pharmaceuticals: Major | Chairman | |
EVEREST MEDICINES LIMITED | Pharmaceuticals: Major | Director/Board Member | |
InxMed Biotechnology Nanjing Co., Ltd.
![]() InxMed Biotechnology Nanjing Co., Ltd. BiotechnologyHealth Technology InxMed Biotechnology Nanjing Co., Ltd. is a clinical-stage biotech company established in 2018, dedicated to developing innovative therapies to overcome treatment resistance, especially anti PD-1/PD-L1 resistance. InxMed is based in Nanjing, China, and has teams located in Shanghai and Beijing, with hubs in San Francisco and Melbourne. The Chinese company's innovations are inspired by patients and driven by in-depth understanding of disease biology and pharmacology. InxMed has raised tens of millions of US dollars in series A round financing and has an integrated high-caliber research and clinical development team across China, the US, and Australia. The company has built a unique innovative pipeline through its own discovery research and development and collaborative research and development. The company was founded in 2018 by Fei Cao and Zai Qi Wang, with Zai Qi Wang serving as the CEO since then. | Biotechnology | Director/Board Member | |
C-Bridge Capital Partners LLC | Corporate Officer/Principal | ||
Weill Cornell Medical College | College/University | Doctorate Degree | |
CBC Group (Singapore) Pte. Ltd.
![]() CBC Group (Singapore) Pte. Ltd. Investment ManagersFinance CBC Group (Singapore) Pte. Ltd.(CBC Group) is a private equity firm founded in 2014 by Wei Fu. The firm is headquartered in Singapore with additional offices in New York, Hong Kong, Shanghai and Beijing and is wholly owned by CBC Group Investment Management Ltd. | Investment Managers | Private Equity Investor | |
PT Kalbe Genexine Biologics
![]() PT Kalbe Genexine Biologics BiotechnologyHealth Technology PT Kalbe Genexine Biologics is a clinical-stage biotech company based in Jakarta, Indonesia. The Indonesian company specializes in licensing novel biologics and biosimilars in oncology and high-specialty therapeutic areas, as well as contract manufacturing. The company was founded in 2016 and is backed by Kalbe and Genexine, as well as US private equity giant General. The CEO is Sie Djohan. | Biotechnology | Director/Board Member | |
I-Mab Bio-tech (Tianjin) Co. Ltd.
![]() I-Mab Bio-tech (Tianjin) Co. Ltd. BiotechnologyHealth Technology I-Mab Bio-tech (Tianjin) Co., Ltd. engages in the research and development of medicine and biological products. Its business activities include investment information consultation, and health information services. The company was founded on April 19, 2012 and is headquartered in Tianjin, China. | Biotechnology | Director/Board Member | |
C-Bridge Capital LLC
![]() C-Bridge Capital LLC Investment ManagersFinance C-Bridge Capital LLC (C-Bridge Capital) is a venture capital subsidiary of CBC Group founded in 2019 by Fu Wei. The firm is headquartered in New York.. | Investment Managers | Private Equity Investor | |
I-MAB Biopharma Co., Ltd.
![]() I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Biotechnology | Director/Board Member |
Statistiques
Internationale
Etats-Unis | 8 |
Chine | 6 |
Corée du Sud | 3 |
Singapour | 2 |
Indonésie | 2 |
Sectorielle
Health Technology | 10 |
Finance | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Opérationnelle
Director/Board Member | 6 |
Corporate Officer/Principal | 6 |
Private Equity Investor | 4 |
President | 2 |
Doctorate Degree | 1 |
Relations les plus connectées
Insiders | |
---|---|
Michael Keyoung | 17 |
- Bourse
- Insiders
- Sasha A. Blaug
- Connexions Sociétés